# A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

> **NCT06192576** · — · RECRUITING · sponsor: **Sanofi** · enrollment: 10 (estimated)

## Conditions studied

- Niemann-Pick Diseases
- Acid Sphingomyelinase Deficiency

## Interventions

- **DRUG:** Olipudase alfa

## Key facts

- **NCT ID:** NCT06192576
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-16
- **Primary completion:** 2029-01-02
- **Final completion:** 2029-01-15
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06192576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06192576, "A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06192576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*